{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:16:24Z","timestamp":1773281784155,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40119-023-00301-0","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T04:43:19Z","timestamp":1674276199000},"page":"185-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-analysis of Randomized Controlled Studies"],"prefix":"10.1007","volume":"12","author":[{"given":"Mohamed","family":"Hamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheref A.","family":"Elseidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Elkheshen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Elmoghrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Zaghloul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Panakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidakpal","family":"Panaich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4248-781X","authenticated-orcid":false,"given":"Ayman","family":"Elbadawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"key":"301_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jcrc.2020.02.011","volume":"57","author":"S Tchen","year":"2020","unstructured":"Tchen S, Sullivan JB. Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock. J Crit Care. 2020;57:148\u201356.","journal-title":"J Crit Care"},{"issue":"1","key":"301_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13613-019-0498-7","volume":"9","author":"TWL Scheeren","year":"2019","unstructured":"Scheeren TWL, Bakker J, De Backer D, et al. Current use of vasopressors in septic shock. Ann Intensive Care. 2019;9(1):20.","journal-title":"Ann Intensive Care"},{"issue":"18","key":"301_CR3","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMra1208943","volume":"369","author":"JL Vincent","year":"2013","unstructured":"Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369(18):1726\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"301_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12871-017-0339-x","volume":"17","author":"MH Anstey","year":"2017","unstructured":"Anstey MH, Wibrow B, Thevathasan T, et al. Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial). BMC Anesthesiol. 2017;17(1):47.","journal-title":"BMC Anesthesiol"},{"issue":"5","key":"301_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jcrc.2013.05.021","volume":"28","author":"AR Levine","year":"2013","unstructured":"Levine AR, Meyer MJ, Bittner EA, et al. Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions. J Crit Care. 2013;28(5):756\u201362.","journal-title":"J Crit Care"},{"issue":"1","key":"301_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13054-018-1967-3","volume":"22","author":"B Levy","year":"2018","unstructured":"Levy B, Fritz C, Tahon E, et al. Vasoplegia treatments: the past, the present, and the future. Crit Care. 2018;22(1):52.","journal-title":"Crit Care"},{"issue":"2","key":"301_CR7","first-page":"139","volume":"11","author":"A Kimmoun","year":"2013","unstructured":"Kimmoun A, Ducrocq N, Levy B. Mechanisms of vascular hyporesponsiveness in septic shock. Curr Vasc Pharmacol. 2013;11(2):139\u201349.","journal-title":"Curr Vasc Pharmacol"},{"key":"301_CR8","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1007\/s11845-021-02903-w","volume":"191","author":"DHE Adly","year":"2022","unstructured":"Adly DHE, Bazan NS, El Borolossy RM, et al. Midodrine improves clinical and economic outcomes in patients with septic shock: a randomized controlled clinical trial. Ir J Med Sci. 2022;191:2785\u201395.","journal-title":"Ir J Med Sci"},{"issue":"8","key":"301_CR9","doi-asserted-by":"publisher","first-page":"e2013913","DOI":"10.1001\/jamanetworkopen.2020.13913","volume":"3","author":"SM Bagshaw","year":"2020","unstructured":"Bagshaw SM, Tran DT, Opgenorth D, et al. Assessment of costs of avoidable delays in intensive care unit discharge. JAMA Netw Open. 2020;3(8):e2013913\u2013e2013913.","journal-title":"JAMA Netw Open"},{"key":"301_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5152\/dcbybd.2011.12","volume":"2","author":"G Aygencel","year":"2011","unstructured":"Aygencel G, Turkoglu M. Characteristics, outcomes and costs of prolonged stay ICU patients. Turk J Med Surg Intensive Care. 2011;2:53\u20138.","journal-title":"Turk J Med Surg Intensive Care"},{"issue":"13","key":"301_CR11","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","volume":"277","author":"PA Low","year":"1997","unstructured":"Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046\u201351.","journal-title":"JAMA"},{"key":"301_CR12","first-page":"6448504","volume":"2022","author":"AT Ahmed Ali","year":"2022","unstructured":"Ahmed Ali AT, Abd El-Aziz MA, Mohamed Abdelhafez A, et al. Effect of oral vasopressors used for liberation from intravenous vasopressors in intensive care unit patients recovering from spinal shock: a randomized controlled trial. Crit Care Res Pract. 2022;2022:6448504.","journal-title":"Crit Care Res Pract"},{"issue":"10","key":"301_CR13","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1007\/s00134-020-06216-x","volume":"46","author":"P Santer","year":"2020","unstructured":"Santer P, Anstey MH, Patrocinio MD, et al. Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial. Intensive Care Med. 2020;46(10):1884\u201393.","journal-title":"Intensive Care Med"},{"key":"301_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jcrc.2021.11.004","volume":"67","author":"R Costa-Pinto","year":"2022","unstructured":"Costa-Pinto R, Yong ZT, Yanase F, et al. A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: the MAVERIC study. J Crit Care. 2022;67:166\u201371.","journal-title":"J Crit Care"},{"issue":"7","key":"301_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7): e1000100.","journal-title":"PLoS Med"},{"key":"301_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"issue":"7414","key":"301_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"301_CR18","unstructured":"Liu M, Luka B, Kolli R, et al. Use of oral midodrine in weaning-off intravenous vasopressors in patients with septic shock. 2010."},{"issue":"1","key":"301_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/01.ccm.0000648268.34861.39","volume":"48","author":"K Hailu","year":"2020","unstructured":"Hailu K, Allen B, Rottman-Pietrzak K, et al. 15010: impact of adjuvant use of midodrine in septic patients receiving vasopressors in the ICU setting. Crit Care Med. 2020;48(1):771\u2013771.","journal-title":"Crit Care Med"},{"key":"301_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/01.ccm.0000633232.77165.17","volume":"48","author":"M Fiorenza","year":"2020","unstructured":"Fiorenza M, Barkes J, Naik S. 924: adjunctive oral midodrine use in critically ill patients. Crit Care Med. 2020;48:441.","journal-title":"Crit Care Med"},{"issue":"1","key":"301_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/01.ccm.0000528219.66628.6d","volume":"46","author":"E Roach","year":"2018","unstructured":"Roach E, Adie S, Gowan M, et al. 200: impact of oral midodrine on duration of intravenous vasopressor therapy. Crit Care Med. 2018;46(1):82.","journal-title":"Crit Care Med"},{"issue":"4","key":"301_CR22","doi-asserted-by":"publisher","first-page":"A1584","DOI":"10.1016\/j.chest.2019.08.1396","volume":"156","author":"A Nadhim","year":"2019","unstructured":"Nadhim A, Tun Z, Chua LC, et al. The impact of midodrine on duration of vasopressor infusion in patents with septic shock in a community hospital setting. Chest. 2019;156(4):A1584.","journal-title":"Chest"},{"issue":"2","key":"301_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1074248408317709","volume":"13","author":"S Sharma","year":"2008","unstructured":"Sharma S, Lardizabal JA, Bhambi B. Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting. J Cardiovasc Pharmacol Ther. 2008;13(2):94\u20137.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"301_CR24","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.chest.2016.02.657","volume":"149","author":"MR Whitson","year":"2016","unstructured":"Whitson MR, Mo E, Nabi T, et al. Feasibility, utility, and safety of midodrine during recovery phase from septic shock. Chest. 2016;149(6):1380\u20133.","journal-title":"Chest"},{"issue":"3","key":"301_CR25","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/jcpt.12375","volume":"41","author":"LB Poveromo","year":"2016","unstructured":"Poveromo LB, Michalets EL, Sutherland SE. Midodrine for the weaning of vasopressor infusions. J Clin Pharm Ther. 2016;41(3):260\u20135.","journal-title":"J Clin Pharm Ther"},{"key":"301_CR26","first-page":"5588483","volume":"2021","author":"A Al-Abdouh","year":"2021","unstructured":"Al-Abdouh A, Haddadin S, Matta A, et al. Impact of adjuvant use of midodrine to intravenous vasopressors: a systematic review and meta-analysis. Crit Care Res Pract. 2021;2021:5588483.","journal-title":"Crit Care Res Pract"},{"issue":"1","key":"301_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-2999(99)00896-1","volume":"389","author":"JA Garcia-Sainz","year":"2000","unstructured":"Garcia-Sainz JA, Vazquez-Prado J, del Carmen ML. Alpha 1-adrenoceptors: function and phosphorylation. Eur J Pharmacol. 2000;389(1):1\u201312.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"301_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1212\/WNL.51.1.120","volume":"51","author":"RA Wright","year":"1998","unstructured":"Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120\u20134.","journal-title":"Neurology"},{"issue":"5","key":"301_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/clpt.1986.101","volume":"39","author":"PK Zachariah","year":"1986","unstructured":"Zachariah PK, Bloedow DC, Moyer TP, et al. Pharmacodynamics of midodrine, an antihypotensive agent. Clin Pharmacol Ther. 1986;39(5):586\u201391.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"301_CR30","first-page":"447","volume":"37","author":"H Grobecker","year":"1987","unstructured":"Grobecker H, Kees F, Linden M, et al. The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride. Arzneimittelforschung. 1987;37(4):447\u201350.","journal-title":"Arzneimittelforschung"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-023-00301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-023-00301-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-023-00301-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T01:15:14Z","timestamp":1678065314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-023-00301-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["301"],"URL":"https:\/\/doi.org\/10.1007\/s40119-023-00301-0","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,21]]},"assertion":[{"value":"11 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}